Ruchika W Gupta

US Patent:

7833980, Nov 16, 2010

Filed:

Dec 11, 2008

Appl. No.:

12/333133

Inventors:

Mark Mercola - Del Mar CA, US
Ruchika Gupta - San Diego CA, US

Assignee:

The Burnham Institute - La Jolla CA

International Classification:

A61K 38/00

US Classification:

514 12

Abstract:

The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/β-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/β-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.

US Patent:

8039255, Oct 18, 2011

Filed:

Nov 1, 2010

Appl. No.:

12/917393

Inventors:

Mark Mercola - Del Mar CA, US
Ruchika Gupta - San Diego CA, US

Assignee:

The Burnham Institute - La Jolla CA

International Classification:

C12N 5/071

US Classification:

435366

Abstract:

The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/β-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/β-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.

US Patent:

20040014209, Jan 22, 2004

Filed:

Jan 23, 2003

Appl. No.:

10/351275

Inventors:

Andrew Lassar - Newton Center MA, US
Mark Mercola - Del Mar CA, US
Ruchika Gupta - San Diego CA, US
Martha Marvin - Brookline MA, US
Valerie Schneider - Philadelphia PA, US
Eldad Tzahor - Brookline MA, US
Barbara Brott - Boston MA, US
Sergei Sokol - Boston MA, US

International Classification:

C12N015/85
C12N005/08

US Classification:

435/366000, 435/455000

Abstract:

The present invention relates to compositions and methods for stimulating differentiation of stem cells into cardiac cells. The methods of the invention involve contacting a population cells comprising stem cells with at least one Wnt antagonist, such as a polypeptide or polypeptide fragment. In certain embodiments, the methods of the invention involve Dkk proteins or fragments, homologs, derivatives, variants, or peptidomimetics thereof.

US Patent:

7465585, Dec 16, 2008

Filed:

Apr 10, 2007

Appl. No.:

11/786146

Inventors:

Mark Mercola - Del Mar CA, US
Ruchika Gupta - San Diego CA, US

Assignee:

The Burnham Institute - La Jolla CA

International Classification:

G01N 33/00
G01N 33/20
G01N 33/86

US Classification:

436 86, 436 69, 436 74

Abstract:

The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/β-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor prognosis whereas expression of single function Dkk2 or Dkk3 (which inhibit Wnt/β-catenin signaling and promote migration, respectively) correlates with phenotypes reflective of good prognosis. Therefore, the pro-migratory activities of Dkk1 and 3 identified here offer new insights into breast cancer progression and a potential avenue for therapeutic intervention.